Literature DB >> 31218970

Evaluation of long-term cardiac side effects of anthracycline chemotherapy by conventional and non-conventional echocardiographic methods in childhood cancer survivors.

Tamer Yoldaş1, Şule Yeşil2, Selmin Karademir1, Gürses Şahin2, Utku Arman Örün1, Vehbi Doğan1, Senem Özgür1.   

Abstract

OBJECTIVE: Anthracycline chemotherapeutic agents carry the well-recognised risk of cardiac toxicity. The aim of this study was to determine the long-term effect of anthracycline chemotherapy on the biventricular function in childhood cancer survivors using tissue Doppler imaging and two-dimensional speckle tracking echocardiography. PATIENTS AND METHODS: The study included 45 survivors of childhood cancers and 50 healthy age-matched control patients. Cardiac function was prospectively studied with conventional echocardiography, tissue Doppler imaging, and speckle tracking echocardiography after completion of treatment. The same analysis was performed on matched controls.
RESULTS: There was no difference in age, gender, height, and weight between the study and control groups. The mean anthracycline dose was 240 ± 106 mg/m2 and the mean remission duration was 8.2 ± 5 years (1-20 years) in the study group. Conventional echocardiography showed similar ejection fraction, shortening fraction, and left ventricle end-diastolic diameter in both groups. Mitral lateral and septal tissue Doppler imaging showed normal but according to control group relatively sub-normal systolic and diastolic function in patient group. The global longitudinal and circumferential strain and strain rates were significantly lower in the patient group compared to control group. Correlation analysis revealed a negative and significant correlation between total anthracycline dose and global longitudinal and circumferential strain and strain rates.
CONCLUSION: Sub-clinical systolic and diastolic dysfunction may not be detected by conventional echocardiographic methods which are frequently used in daily practice. Sub-clinical systolic and diastolic dysfunction may be detected more sensitively by echocardiographic method such as speckle tracking echocardiography in childhood cancer survivors.

Entities:  

Keywords:  Cardiotoxicity; anthracycline; echocardiography; strain

Mesh:

Substances:

Year:  2019        PMID: 31218970     DOI: 10.1017/S1047951119001094

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  5 in total

Review 1.  Assessment of left-ventricular diastolic function in pediatric intensive-care patients: a review of parameters and indications compared with those for adults.

Authors:  Morgan Recher; Astrid Botte; Jerome Soquet; Jean-Benoit Baudelet; François Godart; Stephane Leteurtre
Journal:  World J Pediatr       Date:  2020-06-06       Impact factor: 2.764

Review 2.  Heart Failure with Preserved Ejection Fraction in Children.

Authors:  Bibhuti Das; Shriprasad Deshpande; Jyothsna Akam-Venkata; Divya Shakti; William Moskowitz; Steven E Lipshultz
Journal:  Pediatr Cardiol       Date:  2022-08-17       Impact factor: 1.838

Review 3.  Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.

Authors:  Valentina Bracun; Joseph Pierre Aboumsallem; Peter van der Meer; Rudolf A de Boer
Journal:  Curr Oncol Rep       Date:  2020-06-09       Impact factor: 5.075

4.  Cardiac Surveillance for Early Detection of Late Subclinical Cardiac Dysfunction in Childhood Cancer Survivors After Anthracycline Therapy.

Authors:  Rosaria Sofia; Veronica Melita; Antonio De Vita; Antonio Ruggiero; Alberto Romano; Giorgio Attinà; Lisa Birritella; Priscilla Lamendola; Antonella Lombardo; Gaetano Antonio Lanza; Angelica Bibiana Delogu
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

5.  Evaluation of Cardiotoxic Effects of Anthracyclines by Tissue Doppler Imaging in Survivors of Childhood Cancer.

Authors:  Munise Caliskan; Pelin Kosger; Zeynep Canan Ozdemir; Birsen Ucar; Ozcan Bor
Journal:  Turk Arch Pediatr       Date:  2021-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.